Compare GSBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | GKOS |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.9M | 10.6B |
| IPO Year | 1996 | 2015 |
| Metric | GSBC | GKOS |
|---|---|---|
| Price | $78.01 | $153.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $65.00 | ★ $126.92 |
| AVG Volume (30 Days) | 71.3K | ★ 601.9K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $2.56 | $27.43 |
| P/E Ratio | $26.23 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $53.76 | $73.16 |
| 52 Week High | $82.91 | $191.62 |
| Indicator | GSBC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.